Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma: a 10-year follow-up
Haematologica. 2024 Mar 28.
doi: 10.3324/haematol.2024.285207.
Online ahead of print.
1 Department of Haematology, Aarhus University Hospital, Aarhus, Denmark; Department of Haematology, Region Hospital Goedstrup, Herning.
2 Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Mathematical Sciences, Aalborg University, Aalborg.
3 Department of Oncology, Kuopio University Hospital Cancer Center, Kuopio, Finland; Faculty of Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio.
4 Department of Oncology, St Olav University Hospital, Trondheim, Norway; Department of Clinical and Molecular Medicine, Norwegian University of science and technology (NTNU), Trondheim, Norway.
5 Department of Radiation Sciences, Umeå University, Umeå, Sweden.
6 Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway.
7 Research Programs Unit/Applied Tumor Genomics Research Program, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki.
8 Department of Oncology, Oslo University Hospital, Oslo, Norway.
9 Department of Oncology, Oslo University Hospital, Oslo, Norway; KG Jebsen Centre for B-cell Malignancies, University of Oslo, Oslo, Norway.
10 Department of Oncology, Skane University Hospital, Lund, Sweden; Medical Oncology, Lund University, Lund, Sweden.
11 Department of Hematology, Aalborg University Hospital, Aalborg.
12 Cancer Centre, Oulu University Hospital, Oulu.
13 Department of Clinical Science and Education, Södersjukhuste, Karolinska Insitutet, Stockholm, Sweden; Haematology Centre, Karolinska University Hospital, Stockholm, Sweden.
14 Department of Haematology, Aarhus University Hospital, Aarhus.
15 Research Programs Unit/Applied Tumor Genomics Research Program, University of Helsinki, Helsinki, Finland; Department of Oncology, Tays Cancer Center, Tampere University Hospital, Tampere. marjukka.pollari@pirha.fi.